AU2012219184A1 - Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity - Google Patents

Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity Download PDF

Info

Publication number
AU2012219184A1
AU2012219184A1 AU2012219184A AU2012219184A AU2012219184A1 AU 2012219184 A1 AU2012219184 A1 AU 2012219184A1 AU 2012219184 A AU2012219184 A AU 2012219184A AU 2012219184 A AU2012219184 A AU 2012219184A AU 2012219184 A1 AU2012219184 A1 AU 2012219184A1
Authority
AU
Australia
Prior art keywords
seq
interleukin
amino acid
cells
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012219184A
Other languages
English (en)
Inventor
Jong Sun Kim
Jae Myun Lee
Sang Woo Park
Joo Chun Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NKmax Co Ltd
Original Assignee
ATGen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ATGen Co Ltd filed Critical ATGen Co Ltd
Publication of AU2012219184A1 publication Critical patent/AU2012219184A1/en
Priority to AU2017202628A priority Critical patent/AU2017202628B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2012219184A 2011-02-14 2012-02-10 Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity Abandoned AU2012219184A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017202628A AU2017202628B2 (en) 2011-02-14 2017-04-20 Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020110012983A KR20120093002A (ko) 2011-02-14 2011-02-14 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
KR10-2011-0012983 2011-02-14
PCT/IB2012/000259 WO2012110878A2 (en) 2011-02-14 2012-02-10 Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017202628A Division AU2017202628B2 (en) 2011-02-14 2017-04-20 Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity

Publications (1)

Publication Number Publication Date
AU2012219184A1 true AU2012219184A1 (en) 2013-09-05

Family

ID=46672988

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012219184A Abandoned AU2012219184A1 (en) 2011-02-14 2012-02-10 Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity
AU2017202628A Ceased AU2017202628B2 (en) 2011-02-14 2017-04-20 Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017202628A Ceased AU2017202628B2 (en) 2011-02-14 2017-04-20 Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity

Country Status (20)

Country Link
US (2) US11442069B2 (enExample)
EP (1) EP2676139B1 (enExample)
JP (5) JP6629497B2 (enExample)
KR (3) KR20120093002A (enExample)
CN (1) CN103370622B (enExample)
AU (2) AU2012219184A1 (enExample)
BR (1) BR112013020454B1 (enExample)
CA (1) CA2826053C (enExample)
CL (1) CL2013002361A1 (enExample)
DK (1) DK2676139T3 (enExample)
EA (1) EA038959B1 (enExample)
ES (1) ES2797549T3 (enExample)
IL (1) IL227952B (enExample)
MX (1) MX361731B (enExample)
MY (1) MY175351A (enExample)
RU (1) RU2635194C2 (enExample)
SG (1) SG192247A1 (enExample)
TW (2) TWI668445B (enExample)
UA (1) UA120697C2 (enExample)
WO (1) WO2012110878A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
US10509034B2 (en) 2013-11-05 2019-12-17 Agency For Science, Technology And Research Bladder carcinoma biomarkers
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2017204446A2 (ko) * 2016-05-24 2017-11-30 울산대학교 산학협력단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
CN106222140A (zh) * 2016-08-04 2016-12-14 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基及其配制方法
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102090698B1 (ko) * 2017-08-24 2020-04-23 연세대학교 산학협력단 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
NZ766453A (en) 2018-02-01 2022-02-25 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
JP7649244B2 (ja) * 2019-02-14 2025-03-19 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 免疫細胞の効力をアッセイするための刺激剤の使用
WO2021041399A1 (en) * 2019-08-29 2021-03-04 Board Of Regents, The University Of Texas System Cell cryopreservation medium
KR20220069018A (ko) * 2019-09-25 2022-05-26 레토 래버러토리즈 컴퍼니 리미티드 재조합 인터류킨-15 유사체
WO2021108389A1 (en) * 2019-11-29 2021-06-03 Nkmax Co., Ltd. Method of producing natural killer cells and compositions thereof
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
CN118488963A (zh) * 2021-12-17 2024-08-13 肯特大学 囊泡中生产重组生物分子的序列和方法
KR20230156518A (ko) 2022-05-06 2023-11-14 (주)다이오진 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
CN115855779A (zh) * 2023-01-18 2023-03-28 山东康华生物医疗科技股份有限公司 一种定量检测nk细胞活性的磁微粒化学发光试剂盒及其检测方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
RU2153332C2 (ru) * 1993-08-09 2000-07-27 Орион Корпорейшн Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP3995248B2 (ja) 2001-08-13 2007-10-24 準二郎 土山 エプスタインバーウイルス陰性のｎｋ細胞株
JP2005517389A (ja) * 2001-11-20 2005-06-16 アトゲン カンパニー リミティッド 環境ストレス耐性を有する新規のペプチド及びこれを含む融合蛋白質
WO2003082206A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
JP2004305095A (ja) 2003-04-07 2004-11-04 Limuloid Science Kk 細胞活性化検出方法
CN1297567C (zh) * 2003-06-13 2007-01-31 马菁 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
CA2533990A1 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
MXPA06005104A (es) 2003-11-05 2007-01-25 Palingen Inc Citotoxicidad de celulas b aumentada en anticuerpos de enlace a cdim.
KR100565764B1 (ko) 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질
WO2005108423A1 (en) 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
JP4653465B2 (ja) 2004-10-25 2011-03-16 泰信 小林 ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物
EP1901766A2 (en) * 2005-04-08 2008-03-26 Morningside Venture Investments Limited Use of fril proteins for reducing the production of pro-inflammatory cytokines
EP2047246A4 (en) * 2006-07-28 2009-11-04 Univ New York State Res Found METHOD AND KITS FOR MEASURING THE LYMPHOCYTE FUNCTION
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
AU2008204433B2 (en) 2007-01-11 2014-03-13 Novo Nordisk A/S Anti-KIR antibodies, formulations, and uses thereof
EP2048237A1 (en) * 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Also Published As

Publication number Publication date
JP6629497B2 (ja) 2020-01-15
DK2676139T3 (da) 2020-06-15
TWI668445B (zh) 2019-08-11
KR20120093002A (ko) 2012-08-22
RU2013141487A (ru) 2015-03-27
TW201741670A (zh) 2017-12-01
JP2014510517A (ja) 2014-05-01
JP2017129597A (ja) 2017-07-27
JP6798922B2 (ja) 2020-12-09
CA2826053C (en) 2021-05-25
EP2676139A4 (en) 2014-12-03
SG192247A1 (en) 2013-09-30
RU2635194C2 (ru) 2017-11-09
BR112013020454A2 (pt) 2016-10-18
CN103370622B (zh) 2018-02-13
AU2017202628A1 (en) 2017-05-11
EA038959B1 (ru) 2021-11-15
TW201245718A (en) 2012-11-16
BR112013020454A8 (pt) 2022-11-29
JP2019207242A (ja) 2019-12-05
NZ710432A (en) 2017-04-28
BR112013020454B1 (pt) 2023-03-21
CA2826053A1 (en) 2012-08-23
WO2012110878A3 (en) 2013-01-31
EP2676139A2 (en) 2013-12-25
KR101438573B1 (ko) 2014-09-12
CN103370622A (zh) 2013-10-23
UA120697C2 (uk) 2020-01-27
MY175351A (en) 2020-06-22
EA201391187A1 (ru) 2013-12-30
JP2023115006A (ja) 2023-08-18
WO2012110878A2 (en) 2012-08-23
KR20130032410A (ko) 2013-04-01
ES2797549T3 (es) 2020-12-02
US20220229070A1 (en) 2022-07-21
KR101341538B1 (ko) 2013-12-18
US12379384B2 (en) 2025-08-05
KR20130136012A (ko) 2013-12-11
MX361731B (es) 2018-12-14
JP2022043119A (ja) 2022-03-15
MX2013009380A (es) 2013-12-16
US20140017713A1 (en) 2014-01-16
EP2676139B1 (en) 2020-05-06
US11442069B2 (en) 2022-09-13
AU2017202628B2 (en) 2019-08-22
NZ614345A (en) 2015-09-25
IL227952B (en) 2019-01-31
CL2013002361A1 (es) 2014-06-27
IL227952A0 (en) 2013-09-30
TWI681191B (zh) 2020-01-01
JP7660605B2 (ja) 2025-04-11

Similar Documents

Publication Publication Date Title
US12379384B2 (en) Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity
JPWO2008001944A1 (ja) 自己抗体検出用試薬及び自己免疫疾患の診断キット
JP6169101B2 (ja) 炎症性疾患の予防及び／又は治療において有用な化合物を同定するスクリーニング法
KR20140083986A (ko) 항wt1 항체의 측정 방법
NZ710432B2 (en) Method and use for measurement of nk cell activity
NZ614345B2 (en) Method and use for measurement of nk cell activity
HK1189273B (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
HK1189273A (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
Class et al. Patent application title: SCREENING METHODS TO IDENTIFY COMPOUNDS USEFUL IN THE PREVENTION AND/OR TREATMENT OF INFLAMMATORY CONDITIONS Inventors: Reginald Christophe Xavier Brys (Mechelen, BE) Reginald Christophe Xavier Brys (Mechelen, BE) Sonia Dupont (Romainville, FR) Assignees: GALAPAGOS NV

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted